Uterine Cancer Recurrence: What to Ask

"Uterine cancer" is doing too much work. NCI keeps two separate summaries, and for good reason.

Endometrial carcinoma begins in the lining. Uterine sarcoma begins in the muscle wall, or in the supporting tissue. NCI reports that leiomyosarcoma makes up 30 percent of uterine sarcomas. It arises from muscle. Its peak is around age 50.

At recurrence the two diverge completely. So the first job is working out which page applies.

FIGO's 2023 staging did something unusual. It folded molecular results into the stage itself.

NCI describes four classes and encourages testing for all of them. They are POLEmut, MMRd, NSMP and p53abn. The outlooks differ. A POLE mutation carries a good prognosis, and NCI notes that adjuvant therapies are avoided in that group. That is NCI's general statement about the subtype rather than a rule that settles an individual case, so ask how it reads against the rest of your pathology. Mismatch repair deficiency and no specific molecular profile sit in the middle. Abnormal TP53 carries a poor prognosis.

Two of the four change the stage that gets written down. In early disease, POLEmut and p53abn shift the FIGO stage. That is shown by a small "m" and a subscript. MMRd and NSMP are recorded but do not shift it.

NCI adds a detail worth asking about. The classification can be done on the biopsy. If it was, it need not be repeated on the tissue taken at surgery. NCI also says one group gains most from it. Without this testing, high-grade endometrioid tumors cannot be put in a risk group at all.

For endometrial carcinoma, NCI names the strongest drivers of recurrence. They are grade 3 tissue and deep growth into the muscle wall, where the cancer has not spread outside the uterus.

Vaginal brachytherapy is the treatment aimed at the commonest local site. In PORTEC-2, NCI reports, brachytherapy and external beam radiation matched at five years for vaginal recurrence, locoregional recurrence and survival in stage I disease, and the brachytherapy group had significantly fewer gastrointestinal side effects and better quality of life. That is why NCI calls brachytherapy the preferred adjuvant option in stage I. Over twenty years of follow-up in the Norwegian Radium Hospital trial, adding external beam radiation to brachytherapy did not change overall survival — median 20.5 years against 20.48 — but it raised the risk of second cancers (hazard ratio 1.42). In a post hoc look at women under 60 at entry, the external beam arm had higher mortality and roughly double the second-cancer risk.

Uterine sarcoma is tracked differently. NCI organizes its data by subtype, not by site.

One more endometrial finding is worth knowing, because it settles an old argument. GOG-LAP2 randomly assigned 2,616 patients with early disease to staging surgery by keyhole or by open operation. Recurrence at three years was 10.24 percent after open surgery and 11.39 percent after keyhole. The gap was smaller than the limit set in advance. Even so, NCI notes the formal test for non-inferiority was not met, because both groups had fewer recurrences than the trial expected.

This is the honest answer to the question people most want settled.

Neither NCI summary publishes a surveillance schedule. There is no stated interval for scans. None for examinations. And no blood marker is recommended for tracking either disease. Where a specific schedule has been given, it is fair to ask which guideline it came from. It is not coming from these pages.

That absence shifts the weight onto symptoms. New vaginal bleeding. A growing abdomen. New pelvic pain. Swelling in one leg. New breathlessness. Each is a reason to call rather than wait for the next visit.

The last few years rewrote this section. The numbers are worth carrying.

RUBY. Chemotherapy with or without dostarlimab, in stage III, stage IV or recurrent disease. After about two years, the dostarlimab group had a 36 percent lower risk of progression or death. In mismatch repair deficient disease the drop was 72 percent. Overall survival moved too.

KEYNOTE-868. Carboplatin and paclitaxel with pembrolizumab or placebo, in 810 patients. In deficient tumors, one-year progression-free survival was 74 percent with pembrolizumab and 38 percent with placebo. In proficient tumors, median progression-free survival was 13.1 months against 8.7.

Study 309/KEYNOTE-775. Pembrolizumab with lenvatinib against the doctor's choice of chemotherapy, after a platinum regimen failed. Median progression-free survival was 7.3 months against 3.8. Median overall survival was 18.7 months against 11.9. NCI notes the benefit held whatever the mismatch repair status. Carcinosarcoma and sarcoma were excluded from that trial.

One negative result belongs here too. KEYNOTE-B21 added pembrolizumab after surgery in 1,095 patients with newly diagnosed high-risk stage I to IVA disease. Two-year disease-free survival was 75 percent with pembrolizumab and 76 percent with placebo — no gain overall. Only the mismatch repair deficient group gained, at 92.4 percent against 80.2 percent.

NCI's language here is unusually direct: there is currently no standard therapy, and these patients should enrol in a trial. We are quoting it rather than softening it. It means there is no single agreed regimen, not that nothing is offered. Treatment is still given, chosen for the exact subtype, and a trial is one route among them rather than the only one.

What activity exists is tied to subtype, and the gaps are large. These are response rates from particular studies, not survival, and not an order of preference for your treatment; they are here to show why the subtype line on your pathology report has to be right before anything else is decided. Take ifosfamide, in people not given chemotherapy before. The response rate was 32.2 percent in carcinosarcoma. It was 33 percent in endometrial stromal sarcoma. In leiomyosarcoma the partial response rate was 17.2 percent. Cisplatin has activity in carcinosarcoma. NCI calls it inactive in leiomyosarcoma, first-line or second. Gemcitabine plus docetaxel gave a 53 percent response rate in leiomyosarcoma that could not be removed.

For carcinosarcoma there is a randomized answer. GOG-0161 compared ifosfamide alone with ifosfamide plus paclitaxel. Response rates were 45 percent against 29 percent. Progression-free survival was 8.4 months against 5.8. Overall survival was 13.5 months against 8.4.

• Is this a carcinoma or a sarcoma, and which subtype exactly?
• Which molecular class was assigned, and on which specimen?
• Will the recurrence be biopsied, and will testing be repeated on it?
• Does my mismatch repair status open a specific immunotherapy option?
• Is there a trial open, given that NCI names no standard therapy here?
• What symptoms should prompt a call before the next appointment?

See uterine cancer for the wider picture. See biomarker testing for what the molecular panel involves. And see getting a second opinion if the subtype is in doubt.

There is no blood marker here, and no published scan interval. That puts more weight on symptoms than it does in other cancers.

• Call 911 or go to an emergency department if you have chest pain, sudden breathlessness, cough up blood, or faint. A swollen painful leg followed by any of these can mean a clot has moved to the lung.
• Call your care team the same day if vaginal bleeding is heavy or will not stop, or if you have severe abdominal pain with repeated vomiting and cannot pass gas or stool. That combination can mean the bowel is blocked.
• Call your care team the same day if one leg becomes swollen, painful, warm or red.
• Call your care team within a day or two if you notice any new vaginal bleeding, a growing abdomen, or new pelvic pain.

• NCI PDQ — Endometrial Cancer Treatment (Health Professional Version)
• NCI PDQ — Uterine Sarcoma Treatment (Health Professional Version)
• MedlinePlus — Deep venous thrombosis
• MedlinePlus — Intestinal obstruction